Atopic DermatitisFeatured PodcastPodcast Highlights

Perspectives on Managing Moderate-to-Severe Atopic Dermatitis

By March 30, 2021April 1st, 2022No Comments

JDD Multimedia

JDD Podcast

Listen Now

How to Listen

Perspectives on Managing Moderate-to-Severe Atopic Dermatitis

Drs. April Armstrong, Lawrence Eichenfield & Adam Friedman

 

The Ps of Lichen Planus got nothing on this alliteration filled podcast that was purposefully positioned to perfect your practice prowess to punish the pruritus and picking of AD. Join host Dr. Adam Friedman in part four of five of this Atopic Dermatitis dedicated series as he parties with and picks the brains of dermatology powerhouses Dr.s April Armstrong and Lawrence Eichenfield on pursuing a practical and powerful process to partner with patients of all ages and partake in a long standing management strategy. Please do not push this one off – I promise it is educational perfection. (That’s 24 Ps!)
Listen Now
Learning Objectives
Upon completion of this podcast participants should be able to:

  • Discuss management strategies for patients with moderate-to-severe atopic dermatitis
  • Identify common co-morbidities of atopic dermatitis and strategies for optimal patient care
This podcast is supported by an independent medical education grant provided by Sanofi Genzyme & Regeneron Pharmaceuticals.
Disclosures

April W. Armstrong, MD, MPH – No disclosures.

Lawrence F. Eichenfield, MD – Grant/Research Support: Abbvie, Pfizer, Regeneron, Sanofi-Genzyme, Ortho Derm, Verrica. Consultant: Almirall, Arcutis, Asana, Dermavant, Dermira, Forte, Galderma, Incyte, Leo Pharma, Lilly, Novartis, OrthoDerm. Speakers’ Bureau: Pfizer, Regeneron, Sanofi-Genzyme.

Adam Friedman, MD, FAAD – Grant/Research: Aclaris, CPN, Almirall. Consultant: SanovaWorks, Oakstone Institute, L’oreal, La Roche Posay, Galderma, Aveeno, Valeant, Microcures, Biogen, Pfizer, G&W Laboratories, Novartis, Occulus, Intraderm, Encore, Exeltis, Menlo, Lilly, Aclaris, Dermira, Berg, Allergan, Zylo Therapeutics, Hoth. Speakers’ Bureau: Regeneron, Dermira, Janssen, AbbVie. Major Stock Shareholder: Zylo, Minorcures.

You May Also Like

Formulation Foundations: A Peak Behind the Development Curtain

| Dermatology Podcast Archives, Featured Podcast, JDD Highlights, Podcast Highlights | No Comments
iTunes TuneIn Spotify Dr. David Osborne Finding the right formulation is not always a fun endeavor for the practitioner or patient, and can be the make or break for patient…

Reface the Chase: Paradigm shifts in the AD Management Strategy Mentality

| Dermatology Podcast Archives, Featured Podcast, JDD Highlights, Podcast Highlights | No Comments
iTunes TuneIn Spotify Dr. Raj Chovatiya Who doesn't love a good game of "Whack a Mole?" Anyone? Just as you try to stay ahead of those furry, taunting, smiling devils…

Diving into Dyspigmentation: Discoloration Details and Future Directions

| Dermatology Podcast Archives, Featured Podcast, JDD Highlights, Podcast Highlights | No Comments
iTunes TuneIn Spotify Dr. Andrew Alexis Dyspigmentation is defeating....for the patient and the practitioner as it is often a secondary feature of chronic inflammatory skin diseases and often a greater…

Leave a Reply